Medtronic, Inc. Earnings: Will Medical Devices Bounce Back?

Medtronic remains a leader in the medical-device industry, but spending trends have been poor. Will the market reverse itself?

May 16, 2014 at 6:30PM

Next Tuesday, Medtronic (NYSE:MDT) will release its quarterly report, and investors have recently sent shares of the medical-device giant to all-time record highs. Even though Medtronic and rivals Johnson & Johnson (NYSE:JNJ) and Boston Scientific (NYSE:BSX) have had to deal with rapid changes in the health-care industry, Medtronic hopes that some of the headwinds that have kept down revenue and earnings growth could finally dissipate in the near future, and that could help boost the stock even further.

Medtronic is a leader in the medical-device industry, with products ranging from cardiac pacemakers and defibrillators to stents, grafts, and other methods of supporting cardiovascular health. Yet with all the changes in health care associated with the implementation of the Affordable Care Act, Medtronic has had to adjust to budget pressures from some of its major health-care provider customers. Can Medtronic bounce back from that sluggishness? Let's take an early look at what's been happening with Medtronic over the past quarter and what we're likely to see in its report.

Mdt Pacemakers
Source: Medtronic.

Stats on Medtronic

Analyst EPS Estimate


Change From Year-Ago EPS


Revenue Estimate

$4.58 billion

Change From Year-Ago Revenue


Earnings Beats in Past 4 Quarters


Source: Yahoo! Finance.

What's next for Medtronic earnings?
Investors have been mostly stable in their views on Medtronic earnings in recent months, just clipping a single penny per share from their views for the 2015 fiscal year. The stock has kept climbing, with a rise of almost 7% since mid-February.

Medtronic's fiscal third-quarter report showed some of the challenges that the company faces in the current health-care environment. Revenue rose 3.4%, with emerging markets sales soaring 12% to help lift Medtronic's overall results. But adjusted net income dropped 3% due to the loss of tax incentives, costs from Obamacare, and a writedown related to the failure of a clinical trial. Those results are consistent with the difficulties that Boston Scientific and Johnson & Johnson have had in getting the growth they wanted from their respective medical-device businesses.

In particular, Medtronic has seen tough times lately in the cardiac rhythm management industry, as European sales have slowed and competition from Boston Scientific and other players has intensified. For its part, Medtronic has introduced smaller heart monitors to unlock new growth opportunities. But with Boston Scientific getting approval for new devices, Medtronic has to make sure its research and development efforts keep up with its peers in order to sustain its grip on the market.

Mdt Minimed

MiniMed 530G. Source: Medtronic.

But one area of great potential is Medtronic's diabetes division, which saw revenue jump 16% last quarter. With the introduction of its MiniMed 530G artificial pancreas system, Medtronic is focusing on a disease that has seen a huge rise in incidence. Johnson & Johnson is attempting to make an artificial pancreas that goes further than the MiniMed, but Medtronic's first-mover advantage could give it an important leg up in drawing and keeping new customers.

In the Medtronic earnings report, watch to see where the medical-device maker sees its greatest opportunities going forward. If the health-care industry finally loosens its purse strings and starts spending on equipment again, then Medtronic is in a good position to compete against Johnson & Johnson and Boston Scientific for its fair share of the resulting revenue.

Invest in the next wave of health care innovation
The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it's "the next trillion dollar industry." And the technology behind is poised to set off one of the most remarkable health care revolutions in decades. The Motley Fool's exclusive research presentation dives into this technology’s true potential, and its ability to make life-changing medical solutions never thought possible. To learn how you can invest in this unbelievable new technology, click here now to see our free report.

Click here to add Medtronic to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Dan Caplinger has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson and Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information